{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-187702","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2023-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.406642+00:00","generated_at":"2026-06-13T07:51:20.099182+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Janux reports ~$304M cash; JANX007 interim data show PSA drops 31-67% in 4/5 patients","bullets":["Preliminary cash, equivalents, and short-term investments ~$304.1M as of June 30, 2023.","JANX007 Phase 1a: 4 of 5 patients at flat doses (100-300µg) achieved PSA reductions of 31-67%.","No dose-limiting toxicities; CRS Grade 1-2 only in patients with PSA reductions; no Grade 3 CRS.","PK shows prolonged TRACTr exposure and lack of TCE accumulation, consistent with tumor activation.","Development moving into step-dosing and dose optimization to enhance efficacy with manageable safety."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-187702","json":"https://secwatch.observer/filing/0001193125-23-187702.json","markdown":"https://secwatch.observer/filing/0001193125-23-187702.md","text":"https://secwatch.observer/filing/0001193125-23-187702.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000119312523187702/0001193125-23-187702-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000119312523187702/d526906d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T07:51:20.099182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}